Rodrigo Andres

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3443330/publications.pdf

Version: 2024-02-01

63 papers	11,573 citations	117625 34 h-index	118850 62 g-index
67 all docs	67 docs citations	67 times ranked	21517 citing authors

#	Article	IF	Citations
1	RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0150921.	3.2	10
2	Roscovitine Worsens Mycobacterium abscessus Infection by Reducing DUOX2-mediated Neutrophil Response. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 439-451.	2.9	2
3	Development of Inhibitors of SAICAR Synthetase (PurC) from Mycobacterium abscessus Using a Fragment-Based Approach. ACS Infectious Diseases, 2022, 8, 296-309.	3.8	10
4	Discovery of Novel Inhibitors of Uridine Diphosphate-N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients. Journal of Medicinal Chemistry, 2022, 65, 2149-2173.	6.4	5
5	Sounds of COVID-19: exploring realistic performance of audio-based digital testing. Npj Digital Medicine, 2022, 5, 16.	10.9	48
6	Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses. Nature Communications, 2022, 13, 2692.	12.8	21
7	Exploring Longitudinal Cough, Breath, and Voice Data for COVID-19 Progression Prediction via Sequential Deep Learning: Model Development and Validation. Journal of Medical Internet Research, 2022, 24, e37004.	4.3	16
8	Structural Characterization of Mycobacterium abscessus Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	5
9	The Impact of Hospital-Ward Ventilation on Airborne-Pathogen Exposure. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 766-769.	5.6	8
10	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Research, 2021, 7, 00775-2020.	2.6	4
11	A multicentre analysis of Clostridium difficile in persons with Cystic Fibrosis demonstrates that carriage may be transient and highly variable with respect to strain and level. Journal of Infection, 2021, 82, 363-370.	3.3	4
12	Stepwise pathogenic evolution of Mycobacterium abscessus. Science, 2021, 372, .	12.6	91
13	A paradigm shift to combat indoor respiratory infection. Science, 2021, 372, 689-691.	12.6	192
14	Increased Virulence of Outer Membrane Porin Mutants of Mycobacterium abscessus. Frontiers in Microbiology, 2021, 12, 706207.	3.5	3
15	Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19. Life Science Alliance, 2021, 4, e202000954.	2.8	13
16	Dissemination of Mycobacterium abscessus via global transmission networks. Nature Microbiology, 2021, 6, 1279-1288.	13.3	47
17	Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respiratory Medicine, 2020, 173, 106164.	2.9	21
18	Producing polished prokaryotic pangenomes with the Panaroo pipeline. Genome Biology, 2020, 21, 180.	8.8	419

#	Article	IF	Citations
19	Deletion of cftr Leads to an Excessive Neutrophilic Response and Defective Tissue Repair in a Zebrafish Model of Sterile Inflammation. Frontiers in Immunology, 2020, 11, 1733.	4.8	21
20	How can airborne transmission of COVID-19 indoors be minimised?. Environment International, 2020, 142, 105832.	10.0	933
21	Cell Surface Remodeling of Mycobacterium abscessus under Cystic Fibrosis Airway Growth Conditions. ACS Infectious Diseases, 2020, 6, 2143-2154.	3.8	11
22	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2020, 87, 473-488.	4.1	58
23	Development of Inhibitors against Mycobacterium abscessus tRNA (m¹G37) Methyltransferase (TrmD) Using Fragment-Based Approaches. Journal of Medicinal Chemistry, 2019, 62, 7210-7232.	6.4	32
24	Mabellini: a genome-wide database for understanding the structural proteome and evaluating prospective antimicrobial targets of the emerging pathogen Mycobacterium abscessus. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	12
25	Polymeric nanobiotics as a novel treatment for mycobacterial infections. Journal of Controlled Release, 2019, 314, 116-124.	9.9	23
26	Relative Contributions of Extracellular and Internalized Bacteria to Early Macrophage Proinflammatory Responses to Streptococcus pneumoniae. MBio, 2019, 10, .	4.1	10
27	Germline selection shapes human mitochondrial DNA diversity. Science, 2019, 364, .	12.6	178
28	Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. Cancer Cell, 2019, 35, 767-781.e6.	16.8	91
29	Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2019, 377, 20180422.	3.4	30
30	CFTR Protects against Mycobacterium abscessus Infection by Fine-Tuning Host Oxidative Defenses. Cell Reports, 2019, 26, 1828-1840.e4.	6.4	58
31	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	6.7	54
32	Multiâ€•centre ethics and research governance review can impede nonâ€•interventional clinical research. Internal Medicine Journal, 2019, 49, 722-728.	0.8	11
33	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	5.6	53
34	Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	55
35	Fitting linear mixed models to a highly-structured dataset effectively controls for population structure in bacterial genome-wide association studies. Access Microbiology, 2019, 1, .	0.5	0
36	Examining the Effect of Residual Amikacin on Sputum Culture for Nontuberculous Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 267-269.	5.6	4

#	Article	IF	Citations
37	British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research, 2018, 5, e000348.	3.0	37
38	Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. Frontiers in Neurology, 2018, 9, 870.	2.4	33
39	Latent class analysis to define radiological subgroups in pulmonary nontuberculous mycobacterial disease. BMC Pulmonary Medicine, 2018, 18, 145.	2.0	13
40	Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. European Respiratory Journal, 2017, 49, 1601855.	6.7	94
41	British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72, ii1-ii64.	5.6	488
42	Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72, 969-970.	5.6	55
43	Regulation of phagocyte triglyceride by a STAT-ATG2 pathway controls mycobacterial infection. Nature Communications, 2017, 8, 14642.	12.8	55
44	British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respiratory Research, 2017, 4, e000242.	3.0	93
45	Genomic epidemiology of a national outbreak of post-surgical Mycobacterium abscessus wound infections in Brazil. Microbial Genomics, 2017, 3, e000111.	2.0	22
46	Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF). Journal of Cystic Fibrosis, 2016, 15, 619-623.	0.7	49
47	C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nature Immunology, 2016, 17, 1046-1056.	14.5	123
48	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
49	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax, 2016, 71, 88-90.	5.6	274
50	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
51	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax, 2016, 71, i1-i22.	5.6	348
52	Mycobacterium abscessus Complex Identification with Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry. Journal of Clinical Microbiology, 2015, 53, 2355-2358.	3.9	30
53	Macrophage Migration Inhibitory Factorâ€“CXCR4 Is the Dominant Chemotactic Axis in Human Mesenchymal Stem Cell Recruitment to Tumors. Journal of Immunology, 2015, 194, 3463-3474.	0.8	126
54	Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 293-304.	0.7	170

#	Article	IF	Citations
55	Which microbial factors really are important in Pseudomonas aeruginosa infections?. Future Microbiology, 2015, 10, 1825-1836.	2.0	37
56	The growing threat of nontuberculous mycobacteria in CF. Journal of Cystic Fibrosis, 2015, 14, 1-2.	0.7	23
57	A Spaetzle-like role for nerve growth factor Î² in vertebrate immunity to Staphylococcus aureus. Science, 2014, 346, 641-646.	12.6	68
58	Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet, The, 2013, 381, 1551-1560.	13.7	596
59	Transmission of M abscessus in patients with cystic fibrosis â€“ Authors' reply. Lancet, The, 2013, 382, 504.	13.7	10
60	Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. Journal of Clinical Investigation, 2011, 121, 3554-3563.	8.2	272
61	Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntingtonâ€™s Disease Models and Enhance Killing of Mycobacteria by Macrophages. Autophagy, 2007, 3, 620-622.	9.1	150
62	IFN-Î³- and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of Cathelicidin LL-37. Journal of Immunology, 2007, 178, 7190-7198.	0.8	383
63	Loss of function of a lupus-associated FcÎ³RIIb polymorphism through exclusion from lipid rafts. Nature Medicine, 2005, 11, 1056-1058.	30.7	301